PB (CT) 4010 is a biosimilars humanized monoclonal antibody used for the treatment of various cancers as an angiogenesis incubator. PB (CT) 4010 inhibits a vascular endothelial growth factor that stimulates the formation of new blood vessels.
PB (CT) 4020 is a biosimilar monoclonal human antibody that reverses the effects of an overactive HER2 receptor, the HER2 gene (also known as HER2/new and ErbB2 gene) which is amplified in 20-30% of early stage breast cancers. PB (CT) 4020 works by binding to the domain IV of the extracellular segment of the HER2 Neu receptor, for example to a specific antigen (HER2) on the surface of breast cancer cells to inhibit cell proliferation and growth.
Paras Biopharmaceuticals
Finland Oy,
Kiviharjunlenkki 10, OULU,
FI-90220 Finland
P: +358 442709462
Dr Ashesh Kumar
E: kumar.ashesh@parasbiopharma.com
P: +358 (0) 400207380
Dr Mark Jackson
E: mark.jackson@parasbiopharma.com
P:+358 (0) 442905993
Skype: Paras.Finland
This website uses cookies; by continuing to use this page, you consent to their use. I Understand About Cookies.